Half of psoriasis patients struggle with obesity, creating a therapeutic challenge that dermatologists have largely overlooked despite mounting evidence that excess weight undermines treatment success. This intersection represents a critical gap in care that could be costing patients years of effective disease control.
The research reveals that obesity in psoriasis patients creates a cascade of problems: heightened systemic inflammation, elevated cardiovascular risk, more severe skin disease, and notably reduced effectiveness of expensive biologic therapies. The authors propose specific clinical algorithms where dermatologists take direct responsibility for weight management in patients with BMI under 35 kg/m², while recommending GLP-1 receptor agonists like semaglutide as first-line pharmaceutical intervention for appropriate candidates.
This approach challenges the traditional siloed medical model where dermatologists focus solely on skin manifestations. The evidence supporting integrated care is compelling—obesity fuels the inflammatory pathways that drive psoriasis severity, creating a vicious cycle where heavier patients need more aggressive treatments that work less effectively. The proposed algorithms represent a practical framework for busy dermatology practices, emphasizing universal lifestyle counseling and clear referral criteria for complex cases requiring multidisciplinary intervention. While promising, the recommendation relies heavily on emerging GLP-1 data rather than psoriasis-specific obesity trials. The real test will be whether dermatologists embrace this expanded scope of practice and whether insurance coverage supports these interventions in dermatology settings rather than requiring referrals that often result in fragmented care.